Afamelanotide
PeptideAfamelanotide (Scenesse) is an FDA-approved (2019) prescription drug for erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. It's a synthetic α-MSH analog that stimulates eumelanin production WITHOUT UV exposure. A-GRADE evidence for increasing pain-free sun exposure and reducing phototoxic reactions. B-GRADE for vitiligo repigmentation (with NB-UVB). This is a PRESCRIPTION IMPLANT, not a tanning supplement. Related to but distinct from illegal 'Melanotan II'.
Quick Answer
What it is
Afamelanotide (Scenesse) is an FDA-approved (2019) prescription drug for erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. It's a synthetic α-MSH analog that stimulates eumelanin production WITHOUT UV exposure.
Key findings
- Grade A: Pain-Free Sun Exposure Time (Photodermatoses)
- Grade A: Phototoxic Reactions (Photodermatoses)
- Grade A: Quality of Life (EPP) (Photodermatoses)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Afamelanotide
Quick Facts: Afamelanotide
- Best Evidence:Grade A
- Conditions Studied:3
- Research Outcomes:8
- Grade A Findings:4
- Grade B Findings:2
- Key Effect:Photodermatoses